Mylan Gets FDA Nod for Antidepressant Generics

15 April 2010 (Last Updated April 15th, 2010 18:30)

Mylan Pharmaceuticals has received US FDA approval for its abbreviated new drug application for Bupropion Hydrochloride Extended-Release tablets. The drug is the generic version of GlaxoSmithKline's antidepressant Wellbutrin. FDA approval has been obtained for 100mg, 150mg

Mylan Pharmaceuticals has received US FDA approval for its abbreviated new drug application for Bupropion Hydrochloride Extended-Release tablets.

The drug is the generic version of GlaxoSmithKline's antidepressant Wellbutrin.

FDA approval has been obtained for 100mg, 150mg and 200mg tablets.

According to IMS Health data, Bupropion Hydrochloride Extended-Release Tablets had registered $363m of sales in the USA for 2009.